Monocyte suppressing action of fenofibrate.
Journal Title: Pharmacological Reports - Year 2005, Vol 57, Issue 3
Abstract
Since atherosclerosis has been proven to be an inflammatory disease, itis obvious that the proper treatment for dyslipidemia should not only correct lipid parameters but alsoinhibit inflammation. Monocytes and monocyte-derived proinflammatory cytokines are widely known to beinvolved in the formation and rupture of the atherosclerotic plaque. The aim of our study was to assessthe effect of fenofibrate, a commonly used hypolipidemic drug, on the release of interleukin 1beta (IL-1beta),interleukin 6 (IL-6) and monocyte chemoattractant protein 1 (MCP-1) by monocytes from patients with combinedhyperlipidemia. Fourteen patients with biochemically confirmed type IIb dyslipidemia who did not respondto a low-fat diet were treated with micronized fenofibrate for 1 month. The control group included 12healthy, normolipidemic, age-matched subjects. To accurately evaluate the levels of the inflammatorycytokines, we excluded patients with any inflammatory disease. Monocytes were isolated from peripheralblood before and after the treatment. IL-1beta, IL-6 and MCP-1 release was measured by enzyme-linkedimmunosorbent assay (ELISA) after lipopolysaccharide stimulation. IL-1beta, IL-6 and MCP-1 levels weresignificantly higher in hyperlipidemic patients compared to the control (143.9 +/- 6.5 vs. 74.4 +/- 4.4pg/ml; 8212 +/- 285 vs. 6110 +/- 170 pg/ml; 19.6 +/- 0.9 vs. 12.3 +/- 0.6 ng/ml, respectively). Thirty-dayfenofibrate treatment decreased the release of IL-1beta by 43% (143.9 +/- 6.5 vs. 86.2 +/- 5.9 pg/ml),of IL-6 by 22% (8212 +/- 285 vs. 6330 +/- 234 pg/ml), and of MCP-1 by 29% (19.6 +/- 0.9 vs. 14.0 +/-0.8 ng/ml). The evaluated cytokines were markedly elevated in patients with type IIb dyslipidemia. Effectivefenofibrate therapy had a significant inhibitory effect on the release of monocyte-derived inflammatorycytokines.
Authors and Affiliations
Bogusław Okopień, Jan Kowalski, Robert Krysiak, Krzysztof Łabuzek, Aldona Stachura-Kułach, Andrzej Kułach, Marek Zieliński, Zbigniew Herman
Keywords
Related Articles
- EP ID EP159747
- DOI -
- Views 115
- Downloads 0
Effects of sarcosine, a glycine transporter type 1 inhibitor, in two mouse seizure models.
Sarcosine, a natural amino acid found in muscles and other body tissues, is an endogenous glycine transporter type 1 inhibitor that increases the glycine concentration, resulting in an indirect potentiation of the N-meth...
Monocyte suppressing action of fenofibrate.
Since atherosclerosis has been proven to be an inflammatory disease, itis obvious that the proper treatment for dyslipidemia should not only correct lipid parameters but alsoinhibit inflammation. Monocytes and monocyte-d...
Influence of anticancer therapy on oxidation phenotype and acetylation phenotype in patients with acute myeloblastic leukemia.
The aim of this study was to determine whether antineoplastic cytostatic therapy induces changes in the oxidation or acetylation phenotypes in patients with acute myeloblastic leukemia (AML). The investigations involved...
Effect of N(G)-nitro-L-arginine on the anticonvulsant action of four second-generation antiepileptic drugs in pentetrazole-induced clonic seizures in mice.
The exact role of compounds modulating nitric oxide (NO) content in the brain during seizure phenomena is under intensive investigation. This study was aimed at determining the effect of N(G)-nitro-L-arginine (L-NA; a no...
Urocortin: a protective peptide that targets both the myocardium and vasculature.
The urocortins are a family of endogenously produced peptide hormones that show great promise as potential drugs for the treatment of heart disease. They can increase contractility and cardiac output without causing chan...